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Summary
Background:  Off-pump  coronary  artery  bypass  surgery  and  sirolimus-eluting  stent  placement
have been  widely  used  for  the  treatment  of  coronary  artery  disease.  The  goal  of  this  study  was  to
compare long-term  outcomes  after  off-pump  coronary  artery  bypass  surgery  or  sirolimus-eluting
stent placement  in  diabetic  patients  with  multivessel  disease.
Methods:  This  observational  study  enrolled  350  off-pump  coronary  artery  bypass  patients  and
143 sirolimus-eluting  stent  patients  receiving  care  at  our  institution  between  2000  and  2007.
All patients  had  diabetes  and  multivessel  disease  including  proximal  left  anterior  descending
or left  main  coronary  artery.  The  choice  of  revascularization  (percutaneous  coronary  interven-
tion versus  coronary  artery  bypass  surgery)  was  left  to  the  physician’s  discretion  rather  than
randomization.  Cox  proportional-hazard  analyses,  adjusting  baseline  risk  factors  and  propen-
sity score,  which  predicted  the  probability  of  receiving  off-pump  coronary  artery  bypass,  were
conducted  to  evaluate  outcomes,  including  all-cause  mortality,  cardiac  death,  target  vessel
revascularization,  and  major  adverse  cardiac  and  cerebrovascular  events.
Results: During  the  follow-up  (2.6  ±  1.6  years)  period,  there  was  no  difference  between  off-
pump coronary  artery  bypass  and  sirolimus-eluting  stent  placement  in  all-cause  mortality  or
cardiac death.  However,  the  incidences  of  acute  coronary  syndrome,  target  vessel  revascu-
larization,  and  major  adverse  cardiac  and  cerebrovascular  events  were  markedly  lower  in  the
patients undergoing  off-pump  coronary  artery  bypass  than  in  those  receiving  sirolimus-eluting
stent placement.
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Tokyo, Japan. Tel.: +81 3 5802 1056; fax: +81 3 5689 0627.
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Conclusion:  Off-pump  coronary  artery  bypass  is  superior  to  sirolimus-eluting  stent  place-
ment in  terms  of  acute  coronary  syndrome,  target  vessel  revascularization,  and  major  adverse
cardiac and  cerebrovascular  events  in  diabetic  patients  with  multivessel  coronary  artery
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telephone  interview  or  questionnaires  sent  every  year.  The
details  of  mode  of  death  were  obtained  from  the  medicaldisease.
© 2011  Japanese  College  of  C
ntroduction
oronary  artery  disease  is  the  major  cause  of  mortality  in
atients  with  diabetes  mellitus.  In  fact,  diabetes  patients
ave  a  threefold  higher  risk  of  mortality  from  coronary
rtery  disease  when  compared  with  non-diabetic  subjects
1].  Furthermore,  patients  with  diabetes  undergoing  revas-
ularization  have  increased  mortality  when  compared  with
on-diabetic  patients.
Previous  clinical  studies  have  demonstrated  that  coro-
ary  artery  bypass  surgery  (CABG)  produced  superior
utcomes  in  diabetic  patients  when  compared  with  per-
utaneous  coronary  intervention  (PCI)  [2].  However,  these
tudies  compared  conventional  CABG  to  bare-metal  stents
nd  did  not  study  off-pump  coronary  artery  bypass  surgery
OPCAB)  or  drug-eluting  stents  (DES).  This  is  an  important
imitation  of  previous  studies,  as  OPCAB  is  less  invasive,  uses
ll  in  situ  conduits,  and  employs  aorta  no-touch  techniques,
hich  results  in  a  decreased  incidence  of  intraoperative
omplications  and  in  improvements  in  long-term  outcomes.
urther,  DES  are  associated  with  a  decreased  incidence  of
estenosis  after  PCI  when  compared  with  bare-metal  stents.
Thus,  the  goal  of  this  study  was  to  compare  long-term
utcomes  after  OPCAB  versus  PCI  with  DES  in  diabetic
atients  with  multivessel  coronary  artery  disease.
atients and methods
atients
ata  from  consecutive  patients  with  type  2  diabetes  and
ultivessel  coronary  artery  disease  who  underwent  revas-
ularization  with  placement  of  sirolimus-eluting  stents
Cypher,  Johnson  &  Johnson,  Miami  Lakes,  FL,  USA)  (SES—PCI
roup)  or  OPCAB  surgery  (OPCAB  group)  at  the  Juntendo
eart  Center  (Tokyo,  Japan)  from  July  2002  to  December
008  were  analyzed.  The  management  of  patient  data  was
erformed  according  to  the  ethics  policies  of  our  institution,
nd  this  study  was  approved  by  the  ethics  review  board  of
ur  institution.  Written  informed  consent  was  obtained  from
ll  patients.  Multivessel  disease  was  deﬁned  as  75%  stenosis
n  more  than  two  major  epicardial  vessels  with  proximal  LAD
r  left  main  trunk.
A  total  of  493  patients,  including  350  patients  who  under-
ent  OPCAB  between  July  2002  and  December  2008  and
43  patients  who  underwent  PCI  using  SES  between  2004
nd  2008,  met  the  inclusion  criteria  for  this  study.  Dia-
etes  mellitus  was  deﬁned  as  a  fasting  plasma  glucose
evel  ≥126  mg/dl,  treatment  with  oral  hypoglycemic  medi-
ation,  or  insulin  use.  Hypertension  was  deﬁned  as  systolic
lood  pressure  (BP)  ≥140  mmHg  or  diastolic  BP  ≥90  mmHg,
r  treatment  with  speciﬁc  antihypertensive  medications.
hronic  kidney  disease  was  deﬁned  as  glomerular  ﬁltration
ate  <60  ml/min/1.73  m2,  calculated  by  the  Modiﬁcation  of
r
c
2
uology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
iet  in  Renal  Disease  equation,  or  chronic  dialysis  treat-
ent.  A  current  smoker  was  deﬁned  as  a  patient  who  was
till  smoking  before  hospital  admission  or  who  stopped  smok-
ng  within  1  year  prior  to  the  procedure.
evascularization  procedure
CI  with  SES  was  performed  using  standard  techniques.
reatment  with  aspirin  (100  mg/day)  and  clopidogrel  (75  mg)
r  ticlopidine  (200  mg/day)  was  initiated  72  h  before  PCI
nd  was  continued  indeﬁnitely.  Heparin  was  administered
uring  the  procedure  to  maintain  an  activated  clotting
ime  >250  s.  All  patients  were  scheduled  for  angiographic
ollow-up  at  10  months,  or  earlier  if  angina  symptoms
ccurred.
OPCAB  was  carried  out  according  to  internationally
stablished  techniques.  Arterial  conduits  were  used  when-
ver  possible.  After  surgery,  antiplatelet  therapy  with
spirin  (100  mg/day)  was  continued  indeﬁnitely.  All  patients
ere  scheduled  for  angiographic  or  coronary  computed
omography  evaluation  at  1  year  after  revascularization,  or
arlier  if  angina  symptoms  occurred.
utcomes
utcomes  assessed  in  this  study  were  all-cause  mortal-
ty,  cardiac  death,  target  vessel  revascularization,  acute
oronary  syndrome  (ACS),  and  major  adverse  cardiac  and
erebrovascular  events  (MACCE).  Death  from  myocardial
nfarction,  arrhythmia,  congestive  heart  failure,  or  sudden
eath  was  deﬁned  as  cardiac  death.  Target  vessel  revascu-
arization  was  deﬁned  as  repeated  PCI  or  coronary  artery
ypass  surgery  of  the  target-vessel,  driven  by  clinical  symp-
oms  of  myocardial  ischemia,  or  an  in-lesion  stenosis  of
ore  than  75%  of  the  reference  luminal  diameter  by  visual
stimate.  ACS  included  ACS  with  ST  elevation  which  was
eﬁned  by  the  presence  of  ≥1  mm  ST  elevation  in  at  least
wo  adjacent  limb  leads,  ≥2  mm  ST  elevation  in  at  least
wo  contiguous  precordial  leads,  or  new  onset  left  bun-
le  branch  block,  and  ACS  without  ST  elevation  deﬁned
s  present  of  the  triad  of  clinical  presentation  (including
 history  of  coronary  artery  disease),  electrocardiographic
hanges,  and  biochemical  cardiac  markers.  MACCE  included
ardiac  death,  cerebrovascular  accident,  stroke,  myocar-
ial  infarction,  and  target  vessel  revascularization.  Survival
ata  and  occurrence  of  adverse  events  were  collected  by
erial  contacts  with  the  patients  or  their  families  either  byecords  of  hospitals  or  by  direct  contact  with  private  physi-
ians.  The  database  search  was  performed  at  the  end  of
008,  and  a  common  closing  day  of  December  31,  2008  was
sed  for  analysis.
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Statistical  analysis
For  comparison  of  patients’  characteristics,  categorical  data
are  tabulated  as  frequencies  and  percentages,  and  continu-
ous  variables  are  expressed  as  mean  ±  SD.  These  data  were
analyzed  using  Chi-square  tests  or  Student’s  t-tests.  Survival
curves  of  both  OPCAB  and  SES—PCI  groups  were  constructed
by  Kaplan—Meier  methods  and  were  compared  by  log-rank
test.  Cox  proportional  hazards  models  were  constructed  for
unadjusted  and  adjusted  survival  analyses.
Propensity  analysis  was  applied  to  adjust  variables  that
would  have  been  related  to  the  decision  regarding  revas-
cularization  procedure  and  to  identify  patients  with  similar
probabilities  of  undergoing  OPCAB  based  on  observed  clini-
cal  characteristics.  Propensity  scores  were  then  calculated
for  each  patient  from  the  results  of  the  multivariate  logis-
tic  regression  hazard  analysis.  The  propensity  scores  were
entered  into  the  Cox  proportional  hazard  model  as  con-
tinuous  variables  along  with  the  baseline  covariates.  A
higher  propensity  score  indicated  a  higher  probability  of
undergoing  OPCAB  at  baseline.  Among  17  variables  [age,
gender,  use  of  oral  hypoglycemic  agent,  use  of  insulin,  pres-
ence  of  hypertension,  current  smoker,  hemodialysis,  family
history  of  coronary  artery  disease,  prior  history  of  myocar-
dial  infarction,  presence  of  ACS,  left  ventricular  ejection
fraction  (%),  three-vessel  disease,  left  main  trunk  lesion,
serum  low-density  lipoprotein  (mg/dl),  serum  creatinine
(mg/dl),  and  hemoglobin  A1c  (%)],  covariates  with  a  p-value
less  than  0.20  in  the  univariate  analysis  of  each  endpoint
were  selected  for  the  multivariate  Cox  proportional  haz-
ard  analyses  with  propensity  score.  The  proportional  hazard
assumption  was  checked  by  including  the  interaction  term
between  OPCAB  and  other  covariates  in  this  model.  Haz-
ard  ratios  (HRs)  and  conﬁdence  intervals  (CIs)  of  OCPAB
were  calculated.  A  p-value  of  <0.05  was  considered  to  indi-
cate  an  independent  risk  factor.  All  reported  p-values  are
two-tailed.  All  statistical  analyses  were  performed  using
SPSS  version  15.0  for  Windows  (SPSS  Inc.,  Chicago,  IL,
USA).
Results
Baseline  characteristics
All  consecutive  patients,  who  had  revascularization  during
the  study  period,  completed  follow-up.  Baseline  charac-
teristics  and  clinical  events  during  the  follow-up  period
(2.7  ±  1.6  years)  were  collected  for  all  patients.  Of  the
399  enrolled  patients,  140  (35%)  and  259  (65%)  underwent
SES—PCI  and  OPCAB,  respectively.  Baseline  characteristics
of  the  two  groups  are  summarized  in  Table  1.  Patients
who  underwent  OPCAB  were  likely  to  have  more  severe
coronary  artery  disease  and  were  signiﬁcantly  younger
than  those  who  underwent  SES—PCI.  Patients  undergoing
OPCAB  were  more  likely  to  have  a  history  of  cerebrovas-
cular  accident  and  hypertension  and  have  signiﬁcantly
higher  fasting  blood  sugar  and  hemoglobin  A1c  than
patients  undergoing  SES—PCI.  None  of  the  other  vari-
ables  were  signiﬁcantly  different  when  comparing  the  two
groups.
I
t
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ropensity  analysis
he  variables  used  to  calculate  propensity  score  were
ge,  gender,  history  of  cerebrovascular  events,  number  of
iseased  vessels,  and  left  main  trunk  disease.  The  prop-
rty  of  the  propensity  score  was  checked,  since  the  area
nder  the  receiver  operating  characteristics  (ROC)  curve
as  0.80  (95%  CI,  0.76—0.84,  p  >  0.001),  indicating  excel-
ent  discrimination.  The  Hosmer—Lemeshow  goodness  of  ﬁt
2 for  this  model  was  7.21  (p  =  0.52).  A  higher  propensity
core  in  the  present  study  indicated  an  increased  likelihood
f  undergoing  OPCAB.  OPCAB  patients  had  a  lower  mean
ropensity  score  than  SES—PCI  patients  (0.22  ±  0.19  versus
.43  ±  0.18).
utcomes
 total  of  31  patients  died  from  any  cause,  and  7  patients
ied  from  cardiac  causes.  A  total  of  11  patients  experienced
CS  after  revascularization,  23  patients  underwent  target
essel  revascularization,  and  52  patients  had  MACCE.  Cumu-
ative  survival  curves  of  each  endpoint  are  shown  in  Fig.  1.
ll-cause  and  cardiac  mortality  rates  did  not  signiﬁcantly
iffer  between  OPCAB  group  and  SES—PCI  group.  In  addi-
ion,  there  was  no  difference  in  stroke  between  the  two
roups.  However,  ACS,  target  vessel  revascularization,  and
ACCE  were  signiﬁcantly  lower  in  the  OPCAB  group  than
n  the  SES—PCI  group.  The  results  of  Cox  proportional  haz-
rd  model  adjusted  for  baseline  covariates  and  propensity
core  are  shown  in  Table  2.  There  was  no  difference  in  all-
ause  mortality  (HR,  1.45;  95%  CI,  0.0.47—4.42;  p  =  0.51)  or
ardiac  mortality  (HR,  2.30;  95%  CI,  0.19—27.3;  p  =  0.51)
etween  the  two  groups.  However,  adjusted  hazards  of
CS  and  target  vessel  revascularization  were  signiﬁcantly
ower  in  the  OPCAB  group  than  in  the  SES—PCI  group  (HR,
.28;  95%  CI,  0.01—0.18;  p  <  0.0001;  and  HR,  0.08;  95%  CI,
.02—0.30;  p  <  0.0001).  In  addition,  the  incidence  of  the
omposite  endpoint,  MACCE,  was  also  signiﬁcantly  lower  in
he  OPCAB  group  than  in  the  SES—PCI  group  (HR,  0.14;  95%
I,  0.06—0.30;  p  <  0.0001).
iscussion
he  prevalence  of  diabetes  continues  to  increase  world-
ide.  This  diagnosis  is  associated  with  complicated  coronary
rtery  lesions,  small  vessel  reference  diameter,  diffuse  dis-
ase,  longer  lesion  length,  and  rapid  progression  of  lesions,
ll  of  which  lead  to  worse  outcomes.  Prior  clinical  trials
ave  demonstrated  that  hard  outcomes,  including  death
nd  myocardial  infarction,  were  similar  when  comparing
ABG  and  PCI  but  that  target  vessel  revascularization  and
ngina  relief  were  superior  with  CABG  when  compared  with
CI  [3—5]. Other  previous  clinical  trials  demonstrated  that
ABG  resulted  in  favorable  revascularization  and  reduction
f  death  and  myocardial  infarction  in  diabetic  patients  [6],
nd  thus  this  approach  has  been  the  standard  of  care  for
iabetic  patients  with  multivessel  coronary  artery  disease.
n  addition,  this  study  ﬁrstly  revealed  superiority  of  CABG  in
erms  of  incidence  of  ACS  when  compared  to  PCI  using  DES.
However,  recent  reﬁnements  in  PCI  and  CABG
trategies  may  be  changing  the  paradigm  for  coronary
198  S.  Dohi  et  al.
Table  1  Comparison  of  baseline  characteristics  between  the  two  study  groups.
Off-pump  CABG  SES—PCI  p-Value
Age,  mean  ±  SD  65  ±  9.5  67  ±  8.4  0.044
Gender male,  n  (%)  273  (78%)  121  (85%)  0.12
Body mass  index  (kg/m2),  mean  ±  SD  24  ±  7.9  24  ±  3.2  0.51
Oral hypoglycemic  agents,  n  (%)  162  (46%)  69  (48%)  0.69
Insulin, n  (%)  98  (28%)  34  (24%)  0.34
Hypertension,  n  (%) 254  (73%)  115  (80%)  0.07
Chronic renal  failure,  n  (%) 31  (8.9%) 13  (9.1%)  0.93
Hemodialysis,  n  (%) 29  (8.3%) 12  (8.4%) 0.97
Previous myocardial  infarction,  n  (%) 197  (56%) 47  (33%) <0.0001
History of  cerebrovascular  accident,  n  (%) 36  (10%) 6  (4.4%) 0.037
Peripheral vascular  disease,  n  (%)  22  (6.3%)  11  (8.1%)  0.47
Chronic pulmonary  disease,  n  (%)  8  (2.3%)  4  (3%)  0.67
Left ventricular  ejection  fraction  (%),  mean  ±  SD  55  ±  15  60  ±  11  <0.0001
Hemoglobin  A1c  (%),  mean  ±  SD  7  ±  1.2  6.8  ±  1.2  0.08
Fasting blood  sugar  (mg/dl),  mean  ±  SD  152  ±  53  122  ±  35  <0.0001
Total cholesterol  (mg/dl),  mean  ±  SD  184  ±  42  180  ±  36  0.23
Triglycerides  (mg/dl),  mean  ±  SD  145  ±  104  138  ±  81  0.48
High-density  lipoprotein  (mg/dl),  mean  ±  SD  44  ±  12  44  ±  15  0.72
Low-density  lipoprotein  (mg/dl),  mean  ±  SD  112  ±  35  109  ±  32  0.36
Serum creatinine  (mg/dl),  mean  ±  SD  1.5  ±  1.9  1.5  ±  2.1  0.92
Estimated glomerular  ﬁltration  rate  (60  ml/min/1.73  m2),  mean  ±  SD  61  ±  27  63  ±  24  0.35
Brain natriuretic  peptide  (pg/dl),  mean  ±  SD  239  ±  821  51  ±  43  0.2
Left main  trunk,  n  (%) 112  (32%)  5  (3.5%)  <0.0001
Two-vessel disease,  n  (%) 79  (23%) 71  (50%)  <0.0001
Three-vessel  disease,  n  (%) 246  (70%)  72  (50%)  <0.0001
CABG, coronary artery bypass graft; SD, standard deviation; SES—PCI, sirolimus-eluting stent—percutaneous coronary intervention.
Table  2  Results  of  Cox  proportional  hazard  models.
Hazard  ratio  95%  Conﬁdence  interval  p-Value
All-cause  death
OPCAB  1.45  0.47—4.42  0.51
Age 1.10  1.04—1.16  0.001
Serum creatinine  (mg/dl) 1.11  0.94—1.31  0.22
Left ventricular  ejection  fraction  (%) 0.97  0.94—1.00  0.09
Hemoglobin  A1c  (%) 0.88  0.59—1.31  0.54
Cardiac death
OPCAB  2.30  0.19—27.3  0.51
Age 1.13  1.00—1.28  0.05
Peripheral artery  disease 2.35  0.27—28.8  0.44
Acute coronary  syndrome 12.5  0.93—1.69  0.06
Left ventricular  ejection  fraction  (%) 0.91  0.90—1.03  0.31
Serum low-density  lipoprotein  cholesterol  (mg/dl)  1.04  1.02—1.06  0.001
Acute coronary  syndrome
OPCAB  0.028  0.01—0.18  <0.0001
Hemodialysis  2.10  0.45—9.97  0.35
Three-vessel  disease  0.32  0.081—1.28  0.17
Target vessel  revascularization
OPCAB  0.08  0.024—0.30  <0.0001
Smoking 0.70  0.26—1.89  0.48
Left ventricular  ejection  fraction  (%)  1.01  0.98—1.07  0.18
MACCE
OPCAB 0.14  0.06—0.30  <0.0001
Hypertension  1.38  0.63—3.02  0.41
Serum low-density  lipoprotein  cholesterol  (mg/dl)  1.01  1.00—1.01  0.033
OPCAB, off-pump coronary artery bypass; MACCE, major adverse cardiac and cerebrovascular event.
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Figure  1  Cumulative  survival  or  event-free  rate  of  each  endpoint.  Percentages  indicate  5-year  event-free  rates.  (A)  All-cause
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revascularization  procedures  in  patients  with  diabetes.  For
example,  use  of  DES  has  remarkably  reduced  restenosis
and  target  vessel  revascularization  [7—9]  when  compared
with  BMS,  while  OPCAB  is  less  invasive  and  is  associated
with  a  shorter  operating  time,  and  lower  rates  of  stroke  in
complicated  patients  when  compared  with  traditional  CABG
[10,11].  Thus,  either  of  these  advanced  methods  should
result  in  improvements  in  mortality,  myocardial  infarction,
and  target  vessel  revascularization.
The  present  study  demonstrated  that  outcomes  in  terms
of  MACCE,  target  vessel  revascularization,  and  ACS  were
better  with  OPCAB  than  with  SES—PCI  in  diabetic  patients
with  multivessel  coronary  artery  disease.  However,  there
were  no  signiﬁcant  differences  in  the  incidence  of  all-cause
mortality,  cardiac  death  on  adverse  events  other  than  target
a
i
v
messel  revascularization;  (E)  MACCE  (major  adverse  cardiac  and
essel  revascularization  and  ACS  when  comparing  OPCAB  and
ES—PCI.  These  observations  are  consistent  with  those  from
revious  clinical  studies  that  assessed  conventional  CABG
ersus  PCI  with  plain  old  balloon  angioplasty  or  BMS  [6,12], in
hich  CABG  produced  better  outcomes  in  diabetic  patients.
urther,  Briguori  et  al.  reported  that  1-year  outcomes  were
etter  with  OPCAB  than  with  SES  [13], but  interpretation  of
his  study  was  limited  by  the  short  follow-up  time  period
nd  the  low  number  of  complete  revascularizations  in  the
ES  group.  In  contrast,  Yamagata  et  al.  reported  that  3-year
omposite  endpoints  were  similar  when  comparing  OPCAB
nd  SES  [14]. This  study  differed  from  the  present  study
n  several  factors,  including  the  fact  that  it  was  an  obser-
ational  study,  primary  endpoints  were  different,  and  that
ultivessel  disease  was  deﬁned  as  stenosis  >75%  in  diameter
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n  more  than  two  major  epicardial  vessels  as  opposed  to
75%  stenosis  in  more  than  two  major  epicardial  vessels
ith  proximal  LAD  or  left  main  trunk.  Differences  in  base-
ine  characteristics,  such  as  more  severe  coronary  disease,
ould  explain  the  worse  outcomes  in  our  patients  with  SES
ompared  to  OPCAB.  This  ﬁnding  was  consistent  with  results
rom  the  SYNTAX  trial,  which  demonstrated  that  patients
ith  high  SYNTAX  score  (i.e.  severe  coronary  artery  disease)
ho  underwent  CABG  had  a  lower  rate  of  cardiac  events
ith  compared  with  patients  that  received  a  DES  [15,16].
Japan  is  the  only  country  in  which  >60%  of  isolated
oronary  artery  bypass  surgeries  are  performed  without  car-
iopulmonary  bypass;  OPCAB  is  only  used  about  30%  of  the
ime  in  Western  countries  and  in  other  Asian  countries.  This
ay  be  because  a  previous  study  reported  that  OPCAB  was
ot  signiﬁcantly  superior  to  conventional  CABG  in  terms
f  clinical  outcomes  and  cost-effectiveness  [17]. However,
everal  other  clinical  trials  reported  that  OPCAB  was  asso-
iated  with  decreased  postoperative  morbidity  in  high-risk
atients  when  compared  with  conventional  CABG  [10,11],
nd  another  study  indicated  that  the  beneﬁcial  effect  of
PCAB  extended  beyond  only  those  patients  who  were  at
igh-risk  for  complications.  Indeed,  Hirose  et  al.  demon-
trated  that  the  OPCAB  reduced  the  risk  of  postoperative
ortality  and  morbidity,  as  represented  by  the  EuroSCORE
18],  regardless  of  baseline  patient  characteristics.
PCI  is  used  for  patients  with  more  severe  coronary  artery
isease  in  Japan  when  compared  with  Western  countries.  In
ome  cases,  patients  with  LMT  lesions,  three-vessel  disease,
r  chronic  total  occlusion  are  treated  with  PCI  in  Japan.
he  increased  utilization  of  PCI  in  Japan  has  led  Japanese
urgeons  to  adopt  less  invasive  surgical  procedures  (e.g.
PCAB)  in  order  to  produce  outcomes  that  are  superior  to
hose  achieved  with  PCI.  In  fact,  OPCAB  is  now  the  standard
rocedure  utilized  in  Japan  and  produces  outcomes  that  are
omparable  or  superior  to  conventional  CABG.  Indeed,  out-
omes  with  OPCAB  in  the  present  study  (2-year  mortality
f  10%)  are  much  better  than  historical  results  with  CABG
n  diabetic  patients  with  multivessel  coronary  artery  dis-
ase  (2-year  mortality  of  20%).  This  may  be  partially  due
o  the  fact  that  OPCAB  utilizes  arterial  conduits  or  because
he  cohort  in  the  present  study  beneﬁted  from  advances  in
edical  therapy.
The better  outcomes  in  response  to  OPCAB  relative  to
ES  in  diabetic  patients  with  multi-vessel  disease  can  be
xplained  by  the  presence  of  more  severe  diffuse  disease
n  diabetic  patients  and  by  the  effects  of  disease  progres-
ion.  Despite  medical  therapy,  coronary  artery  disease  can
rogress  in  both  native  coronary  arteries  and  bypass  con-
uits;  however,  grafting  literally  bypasses  the  existing  lesion
nd  any  other  future  culprit  lesions  within  the  diseased  ves-
el,  canceling  out  the  effects  of  lesion  progression  within
he  bypassed  segment  [19,20].  In  contrast,  stenting  does
ot  modulate  lesion  progression  anywhere  else  within  the
iseased  vessel.
This  study  has  several  limitations.  First,  it  was  non-
andomized  and  used  observational  data  from  a  single
enter  well-managed  database.  We  tried  to  minimize  the
ias  inherent  in  observational  studies  by  using  multivariate
nalysis  and  propensity  analysis.  However,  other  unknown
onfounders  may  have  affected  the  outcomes.  Second,  the
hoice  of  speciﬁc  revascularization  therapy  was  left  to  theS.  Dohi  et  al.
iscretion  of  the  interventional  cardiologists  and  cardiac
urgeons,  and  the  absence  of  randomization  may  have  con-
ounded  the  results.  For  example,  higher-risk  patients  (e.g.
iffuse  disease  or  left  ventricular  dysfunction)  that  are  not
raditionally  considered  as  good  candidates  for  OPCAB  may
ave  been  selected  for  OPCAB  nonetheless.  Third,  given  the
isk  of  very  late  thrombosis  with  SES,  a  longer-term  clinical
ollow-up  is  needed  to  assess  the  clinical  safety  of  DES  in
hese  patients.  We  tried  to  minimize  this  effect  by  comput-
ng  a  propensity  score  and  including  it  in  our  calculation  of
he  HR.
In  conclusion,  OPCAB  was  superior  to  SES—PCI  in  terms  of
CS,  target  vessel  revascularization,  and  MACCE  in  diabetic
atients  with  multivessel  coronary  artery  disease.  Further
rospective  study  is  needed  to  elucidate  the  relative  long-
erm  outcomes  of  these  two  procedures.
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